Highest-materiality recent filing
VieMed files investor deck with no new financial metrics or guidance
Investor presentation dated August 2026 furnished for general use.
Viemed Q2 2026 revenue $78.1M record, up 23.9% YoY; raises FY revenue guidance
Net revenue $78.1M (record), up 23.9% YoY; net income $2.8M ($0.07 diluted EPS).
Viemed Healthcare shareholders approve LTIP amendment, increase share reserve to 7.70M
LTIP share reserve increased to 7,696,717 shares, including up to 1M incentive stock options.
Viemed Healthcare files investor presentation with no material updates
Filed investor deck under Item 7.01 Regulation FD; no earnings or guidance provided.
Viemed Healthcare reports Q1 2026 revenue of $75.4M, raises full-year guidance
Net revenues increased 28% to $75.4 million for Q1 2026, up from $59.1 million in Q1 2025.
Viemed files March 2026 investor deck with no material new data disclosed
Investor deck titled 'A Rapidly Growing National Leader In Home-Based Clinical Care' filed as Exhibit 99.1.
Viemed posts record FY2025 revenue $270.3M; net income +33%; guides FY2026 rev $310-320M
Q4 revenue $76.2M (record, +26% YoY); FY revenue $270.3M (record, +21% YoY).
Viemed extends delayed draw term loan commitment to Nov 2026 and furnishes investor presentation
Amendment extends delayed draw term loan commitment expiration from Nov 29, 2025 to Nov 29, 2026.
Viemed Q3 revenue record $71.9M, up 24% YoY; guides FY rev $271-273M
Net revenues $71.9M, a company record, up 24% YoY from $58.0M.
Viemed completes $13.2M share buyback of 1.98M shares (5% of outstanding)
Repurchased 1,976,441 common shares for approximately $13.2M at weighted average price of $6.69 per share.
Viemed Q2 net revenue $63.1M (record, +14.7% YoY); diluted EPS $0.08 vs $0.04
Net revenues for Q2 2025 hit $63.1M, a record high, up 14.7% from $55.0M in Q2 2024.
Viemed closes acquisition of Lehan's Medical Equipment for $26M base plus $2.2M earnout
Base purchase price $26M (subject to adjustments) plus estimated contingent consideration of ~$2.2M.
Viemed authorizes share repurchase of up to 1.98M shares (~5% of outstanding) through June 2026
Board authorized repurchase of up to 1,976,441 common shares (approx. 5% of outstanding) through June 2026.
Shareholders approve amendment to 2024 LTIP, increasing share pool to ~7.9M
Amendment increases maximum shares available under 2024 LTIP to 7,904,769.
Viemed reports Q1 2025 revenue of $59.1M, up 17% YoY; net income rises 64%
Q1 net revenues $59.1M, 17% increase from $50.6M in Q1 2024.
Viemed acquires Lehan's Medical Equipment for $26M base price; diversifies into women's health
Base purchase price $26M, plus ~$2.2M contingent payments; expected close Q3 2025.
Bruce Greenstein resigns from Viemed Healthcare board effective April 14, 2025
Resignation was effective immediately; no replacement has been announced.
Viemed posts March 2025 investor presentation; no specific financial updates in filing
Company furnished an investor deck covering home respiratory care leadership and business overview.
Viemed posts record Q4 revenue $60.7M; full year net revenue $224.3M; issues 2025 guidance
Q4 net revenue $60.7M (+20% YoY); full year $224.3M (+23% YoY).
Viemed files investor presentation; no specific financial details provided in filing
Furnished an investor presentation (Exhibit 99.1) under Item 7.01.
Viemed Healthcare Q3 2024: revenue up 17.4% to $58M, net income up 33%
Net revenues of $58.0M, a company record; up 17.4% YoY and 5.5% sequentially.
Viemed furnishes August 2024 investor deck; no material new disclosures
Presentation provides general business overview and strategy for home respiratory care.
Viemed Q2 2024 revenue hits record $55.0M, up 27% YoY; Adjusted EBITDA up 31%
Net revenues $55.0M (record), up 27% YoY and 9% sequential from Q1 2024.
Viemed shareholders approve 2M-share 2024 LTIP; directors elected with notable withhold votes
Shareholders approved 2024 Long Term Incentive Plan authorizing up to 2,000,000 common shares for equity awards.
Viemed Healthcare extends delayed draw term loan commitment to Nov 2025
Extended delayed draw term loan commitment expiration from May 29, 2024 to November 29, 2025.
Viemed furnishes May 2024 investor deck; no specific new financial data provided in exhibit
Filing is a Regulation FD disclosure of an investor presentation used for meetings.
Viemed Q1 2024 revenue $50.6M, up 28% YoY; net income $1.6M
Net revenues $50.6M for Q1 2024, increase of $11.0M or 28% vs Q1 2023.
Viemed acquires majority stake in East Alabama HomeMed; expects ~$4M annual revenue
Transaction closed April 1, 2024; Viemed gains controlling interest and managerial control of HomeMed.
Viemed files March 2024 investor deck with no specific new financial targets disclosed
Company posted slide deck to investors covering home respiratory care market position.
Viemed reports record Q4 revenue $50.7M (+35% YoY); net income up 43%
Q4 2023 revenue $50.7M, up 35% from $37.5M in Q4 2022; full-year revenue $183.0M, up 32%.
Viemed Healthcare voluntarily delists from TSX; shares to trade solely on NASDAQ
Voluntary delisting from TSX effective after market close on December 21, 2023.
Viemed Healthcare furnishes November 2023 investor deck via 8-K
Filing under Item 7.01 furnishes an investor presentation dated November 2023.
Viemed Healthcare reports record Q3 2023 revenue $49.4M (+38% YoY); net income up 177%
Net revenues of $49.4M, a Company record, up 38% YoY and 14% sequentially from Q2 2023.
Viemed furnishes August 2023 investor presentation; no material new information disclosed
Company furnished an investor deck dated August 2023 under Item 7.01.
Viemed Healthcare reports Q2 2023 record revenue of $43.3M, up 31% YoY
Net revenues of $43.3M for Q2 2023, a new Company record, up 31% YoY; HMP acquisition contributed $2.5M.
Viemed files HMP 2022 financials: $31.85M revenue, net loss $275K
HMP had 2022 revenue of $31.85M and net loss attributable to parent of $275K.
Viemed shareholders reelect all eight directors; Nitin Kaushal receives only 56.33% support
All eight director nominees elected at June 13 annual meeting; Nitin Kaushal had 43.67% votes withheld.
Viemed completes $28M acquisition of Home Medical Products; guides Q2 rev $42.5M-$43.5M
Acquired HMP for ~$28M cash; funded by $15M cash on hand and $13M from existing credit facilities.
Viemed posts May 2023 investor presentation; no material new financial data disclosed
Exhibit 99.1 is an investor deck used for meetings; no earnings or guidance explicitly cited in the filing.
Viemed Q1 2023 revenue record $39.6M, up 31% YoY; EBITDA $8.3M
Net revenue of $39.6M, a record, up 31% from Q1 2022 and 6% sequentially.
Viemed Healthcare to acquire Home Medical Products for $31.75M in cash
Purchase price of $31.75M cash for 100% equity; expected closing in June 2023.
Viemed Healthcare files investor deck for March 2023; no specific financial updates disclosed
Company furnished an investor presentation dated March 2023 as Exhibit 99.1.
Q4 core net revenue $37.5M (record), +30% vs Q4 2021, +5% sequentially.
Viemed wins complete overruling of OIG claims; $0 overpayment, funds returned
ALJ overturned all remaining disputed claims from OIG audit; Medicare contractors returned 100% of previously remitted funds.
Viemed invests $2M in ModoHealth, gains convertible note and network access
Invested $2,000,000 cash in ModoHealth, a value-based care and patient management platform.
Viemed enters $60M senior secured credit facilities with accordion up to $90M
New facilities: $30M revolving credit facility (5-yr) + $30M delayed draw term loan (5-yr), total $60M.
Viemed Healthcare files investor deck for Q4 2022 presentations
Company filed an investor presentation dated November 2022 as Exhibit 99.1 to an 8-K.
Viemed Q3 core revenue $35.8M, +28% YoY; ventilator patients up 11%
Core net revenue of $35.8M for Q3 2022, a record, +28% YoY and +7% sequential.
Viemed Healthcare files 8-K to make investor deck available; no material new information
Filing under Item 7.01 Regulation FD; investor deck attached as Exhibit 99.1.
Viemed Healthcare Q2 2022 core revenue $33.1M record, up 26% YoY; adjusted EBITDA $6.5M
Q2 core net revenues $33.1M (record); total revenues including COVID-19 services $33.3M.
On April 14, 2025, Bruce Greenstein notified Viemed Healthcare, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors, effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event earnings